These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 2958865

  • 1. Effect of surgical and biochemical castration and an antiandrogen on patients with stage D2 prostatic cancer: preliminary results.
    Givner ML, Millard OH.
    Prog Clin Biol Res; 1987; 243A():439-43. PubMed ID: 2958865
    [No Abstract] [Full Text] [Related]

  • 2. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
    Labrie F, Dupont A, Giguère M, Borsanyi JP, Lacourciere Y, Bélanger A, Lachance R, Emond J, Monfette G.
    Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
    [Abstract] [Full Text] [Related]

  • 3. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: today's therapy of choice.
    Labrie F, Dupont A, Cusan L, Giguere M, Bergeron N, Borsanyi JP, Lacourciere Y, Belanger A, Emond J, Monfette G.
    J Steroid Biochem; 1988; 30(1-6):107-17. PubMed ID: 3290578
    [Abstract] [Full Text] [Related]

  • 4. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
    St Arnaud R, Lachance R, Dupont A, Labrie F.
    J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
    [Abstract] [Full Text] [Related]

  • 5. Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide.
    Moorjani S, Dupont A, Labrie F, Lupien PJ, Gagné C, Brun D, Giguère M, Bélanger A, Cusan L.
    J Clin Endocrinol Metab; 1988 Feb; 66(2):314-22. PubMed ID: 3276721
    [Abstract] [Full Text] [Related]

  • 6. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients.
    Labrie F, Dupont A, Giguere M, Borsanyi JP, Lacourciere Y, Belanger A, Lachance R, Emond J, Monfette G.
    J Steroid Biochem; 1987 Feb; 27(1-3):525-32. PubMed ID: 2961937
    [Abstract] [Full Text] [Related]

  • 7. Combined treatment with flutamide and surgical or medical (LHRH agonist) castration in metastatic prostatic cancer.
    Lancet; 1986 Jan 04; 1(8471):48-9. PubMed ID: 2867292
    [No Abstract] [Full Text] [Related]

  • 8. Re Benefits of combination therapy with flutamide in patients relapsing after castration.
    Br J Urol; 1988 Nov 04; 62(5):495-6. PubMed ID: 3208035
    [No Abstract] [Full Text] [Related]

  • 9. A comparative study of a long acting luteinizing hormone releasing hormone agonist (Decapeptyl) and orchiectomy in the treatment of advanced prostatic cancer. Preliminary report.
    De Sy WA, de Meyer JM, Casselman J, De Smet R, Renders G, Schelfhout W, De Wilde P.
    Acta Urol Belg; 1986 Nov 04; 54(2):221-9. PubMed ID: 2942015
    [No Abstract] [Full Text] [Related]

  • 10. Combination therapy with flutamide and castration: its benefits at various stages of prostate cancer.
    Labrie F, Dupont A, Cusan L, Manhès G, Bergeron N, Lacourcière Y, Pineault S, Bélanger A, Monfette G, Emond J.
    Prog Clin Biol Res; 1989 Nov 04; 303():161-7. PubMed ID: 2674982
    [No Abstract] [Full Text] [Related]

  • 11. Major advantages of "early" administration of endocrine combination therapy in advanced prostate cancer.
    Labrie F, Dupont A, Cusan L, Gomez JL, Diamond P.
    Clin Invest Med; 1993 Dec 04; 16(6):493-8. PubMed ID: 8013154
    [Abstract] [Full Text] [Related]

  • 12. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist.
    Labrie F, Dupont A, Belanger A, Lachance R.
    J Urol; 1987 Oct 04; 138(4):804-6. PubMed ID: 3309363
    [Abstract] [Full Text] [Related]

  • 13. Is there a role for pure antiandrogens in the treatment of advanced prostatic cancer?
    Pavone-Macaluso M, Serretta V, Daricello G, Pavone C, Cacciatore M, Romano C, Cavallo N.
    Prog Clin Biol Res; 1990 Oct 04; 350():149-57. PubMed ID: 2201041
    [Abstract] [Full Text] [Related]

  • 14. Combined androgen blockade: leuprolide and flutamide versus leuprolide and placebo.
    Crawford ED, Goodman P, Blumenstein B.
    Semin Urol; 1990 Aug 04; 8(3):154-8. PubMed ID: 2119048
    [No Abstract] [Full Text] [Related]

  • 15. Benefits of combination therapy with flutamide in patients relapsing after castration.
    Labrie F, Dupont A, Giguere M, Borsanyi JP, Lacourciere Y, Monfette G, Emond J, Bergeron N.
    Br J Urol; 1988 Apr 04; 61(4):341-6. PubMed ID: 3289676
    [Abstract] [Full Text] [Related]

  • 16. Flutamide approved for prostate cancer.
    Oncology (Williston Park); 1989 Mar 04; 3(3):135. PubMed ID: 2518157
    [No Abstract] [Full Text] [Related]

  • 17. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival.
    Labrie F, Dupont A, Belanger A, Giguere M, Lacoursiere Y, Emond J, Monfette G, Bergeron V.
    J Steroid Biochem; 1985 Nov 04; 23(5B):833-41. PubMed ID: 2934579
    [Abstract] [Full Text] [Related]

  • 18. Maximal androgen blockade (MAB) for the treatment of prostate cancer.
    Kirby RS.
    Br J Clin Pract; 1996 Nov 04; 50(5):287. PubMed ID: 8794610
    [No Abstract] [Full Text] [Related]

  • 19. Effect of adrenalectomy, flutamide, and leuprolide on the growth of the Dunning rat R-3327 prostatic carcinoma.
    Kung TT, Mingo GG, Siegel MI, Watnick AS.
    Prostate; 1988 Nov 04; 12(4):357-63. PubMed ID: 3134647
    [Abstract] [Full Text] [Related]

  • 20. Decapeptyl in the treatment of advanced prostatic cancer: comparative study with pulpectomy.
    Botto H, Richard F, Mathieu F, Camey M.
    Prog Clin Biol Res; 1989 Nov 04; 303():53-60. PubMed ID: 2528740
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.